Jula Inrig M.D.

Jula Inrig Named to PharmaVoice 100 Top Industry Leaders List for 2022

Monday, September 6, 2022 -- today, our chief medical officer, Jula Inrig, M.D., was named to the PharmaVoice 100 Top Industry Leaders List for 2022. The PharmaVoice 100 awards recognize the most inspiring leaders in the life sciences, as decided by PharmaVoice readers. Jula’s inspiration? Being able to help as many people as possible, “I ask myself, what impact can I have on society today and for the future of health for patients?”

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022.

Read the full press release >

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgA nephropathy, a rare kidney disorder and leading cause of end-stage kidney disease (ESKD). The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.

Read the full press release >
2022 PM 360 Trailblazer Specialty Pharma/Biotech Company of the Year Finalist

Travere Therapeutics Named Finalist for the 2022 PM360 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year Award

Wednesday, August 17, 2022 -- We are thrilled to have been named as a finalist for the 2022 PM30 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year award. Trailblazer finalists are selected by a cross-section of experts from across the industry evaluating companies for innovation, talent development, and social responsibility. Read the full list of finalists.
Bronze 2022 Stevie Winner for Great Employers

Travere Therapeutics Named 2022 Bronze Winner of The Stevie Awards for Great Employers

Tuesday, August 9, 2022 -- We are honored to be recognized by The Stevie Awards for Great Employers as a 2022 bronze award winner. The Stevies recognize some of the world’s best employers who help to create and foster great places to work. Stevie judges noted Travere’s purpose-driven culture, inspiring values, and commitment to employees’ well-being. Read the full list of 2022 winners.

Travere Therapeutics Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update.

Read the full press release >

Travere Therapeutics Provides Regulatory Updates on its Development Programs

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided regulatory updates for its sparsentan programs in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), as well as its pegtibatinase program for classical homocystinuria (HCU).

Read the full press release >
Eric Dube Ernst Young

Eric Dube Named EY Entrepreneur of the Year 2022 Pacific Southwest Award Winner

Ernst & Young today announced that our CEO Eric Dube has been named an Entrepreneur of the Year 2022 Pacific Southwest Award winner! This prestigious award recognizes exemplary leaders who lift up their employees and their communities and are focused on creating a better world for all. A panel of independent judges selected 13 winners out of the 40 finalists who were eligible for the award.

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.

Read the full press release >

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >